Cutaneous cryptococcosis in solid organ transplant recipients

TitleCutaneous cryptococcosis in solid organ transplant recipients
Publication TypeJournal Article
Year of Publication2010
AuthorsSun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff SL, House AA, Houston SH, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N
JournalMed Mycol
Pagination785 - 91
Date PublishedSep
ISSN1460-2709 (Electronic) 1369-3786 (Linking)
Accession Number20100136
KeywordsAntifungal Agents / therapeutic use, Central Nervous System Fungal Infections / epidemiology / mortality, Cohort Studies, Cryptococcosis / complications / drug therapy / mortality / *pathology, Cryptococcus neoformans / *isolation & purification, Dermatomycoses / complications / drug therapy / mortality / *pathology, Female, Fluconazole / therapeutic use, Fungemia / epidemiology / mortality, Humans, Lung Diseases, Fungal / epidemiology / mortality, Male, Middle Aged, Prospective Studies, Transplantation, Transplants / *adverse effects

Clinical manifestations, treatment, and outcomes of cutaneous cryptococcosis in solid organ transplant (SOT) recipients are not fully defined. In a prospective cohort comprising 146 SOT recipients with cryptococcosis, we describe the presentation, antifungal therapy, and outcome of cutaneous cryptococcal disease. Cutaneous cryptococcosis was documented in 26/146 (17.8%) of the patients and manifested as nodular/mass (34.8%), maculopapule (30.4%), ulcer/pustule/abscess (30.4%), and cellulitis (30.4%) with 65.2% of the skin lesions occurred in the lower extremities. Localized disease developed in 30.8% (8/26), and disseminated disease in 69.2% (18/26) with involvement of the central nervous system (88.9%, 16/18), lung (33.3%, 6/18), or fungemia (55.6%, 10/18). Fluconazole (37.5%) was employed most often for localized and lipid formulations of amphotericin B (61.1%) for disseminated disease. Overall mortality at 90 days was 15.4% (4/26) with 16.7% in disseminated and 12.5% in localized disease (P = 0.78). SOT recipients who died were more likely to have renal failure (75.0% vs. 13.6%, P = 0.028), longer time to onset of disease after transplantation (87.5 vs. 22.6 months, P = 0.023), and abnormal mental status (75% vs. 13.6%, P = 0.028) than those who survived. Cutaneous cryptococcosis represents disseminated disease in most SOT recipients and preferentially involves the extremities. Outcomes with appropriate management were comparable between SOT recipients with localized and disseminated cryptococcosis.

Short TitleCutaneous cryptococcosis in solid organ transplant recipients
Notify Library Reference ID1497

Related Incidents